AU2020265676A1 - Dosage regimens for and compositions including anti-RSV antibodies - Google Patents

Dosage regimens for and compositions including anti-RSV antibodies Download PDF

Info

Publication number
AU2020265676A1
AU2020265676A1 AU2020265676A AU2020265676A AU2020265676A1 AU 2020265676 A1 AU2020265676 A1 AU 2020265676A1 AU 2020265676 A AU2020265676 A AU 2020265676A AU 2020265676 A AU2020265676 A AU 2020265676A AU 2020265676 A1 AU2020265676 A1 AU 2020265676A1
Authority
AU
Australia
Prior art keywords
rsv
patient
antigen binding
binding fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020265676A
Other languages
English (en)
Inventor
Anis Ahmed KHAN
Vadryn PIERRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
SANOFI PASTEUR Inc
Original Assignee
MedImmune Ltd
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd, SANOFI PASTEUR Inc filed Critical MedImmune Ltd
Publication of AU2020265676A1 publication Critical patent/AU2020265676A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
AU2020265676A 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-RSV antibodies Pending AU2020265676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
AU2020265676A1 true AU2020265676A1 (en) 2021-11-18

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020265676A Pending AU2020265676A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-RSV antibodies

Country Status (15)

Country Link
US (3) US12024553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962940A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022531205A (cg-RX-API-DMAC7.html)
KR (1) KR20220002427A (cg-RX-API-DMAC7.html)
CN (1) CN113825767A (cg-RX-API-DMAC7.html)
AU (1) AU2020265676A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014370A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192776A1 (cg-RX-API-DMAC7.html)
IL (1) IL287443A (cg-RX-API-DMAC7.html)
MX (1) MX2021013248A (cg-RX-API-DMAC7.html)
SG (1) SG11202111748TA (cg-RX-API-DMAC7.html)
TW (1) TWI861099B (cg-RX-API-DMAC7.html)
WO (1) WO2020223435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20240055097A (ko) * 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Also Published As

Publication number Publication date
TW202106333A (zh) 2021-02-16
MX2021013248A (es) 2022-01-24
WO2020223435A1 (en) 2020-11-05
EP3962940A1 (en) 2022-03-09
CA3138180A1 (en) 2020-11-05
BR112021020846A2 (pt) 2022-01-18
JP2025072444A (ja) 2025-05-09
IL287443A (en) 2021-12-01
US20220204593A1 (en) 2022-06-30
US12024553B2 (en) 2024-07-02
EA202192776A1 (ru) 2022-01-19
US20200347120A1 (en) 2020-11-05
KR20220002427A (ko) 2022-01-06
US20240417447A1 (en) 2024-12-19
CN113825767A (zh) 2021-12-21
JP2022531205A (ja) 2022-07-06
CO2021014370A2 (es) 2021-10-29
TWI861099B (zh) 2024-11-11
SG11202111748TA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
US20240417447A1 (en) Dosage regimens for and compositions including anti-rsv antibodies
AU2021202598B2 (en) Compositions and methods for the treatment of immunodeficiency
Mejias et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
JP7708860B2 (ja) 呼吸器合胞体ウイルスに特異的に結合する分子
CN110418803A (zh) 抗rsv单克隆抗体配制品
AU2023375894A1 (en) Antigen binding molecules targeting sars-cov-2
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
US20240043524A1 (en) Interleukin 5 binding protein dosage regimen
EA046902B1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
RU2807524C2 (ru) Составы антител к rsv и способы их применения
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
WO2026098555A1 (zh) 一种抗rsv抗体在预防和治疗rsv中的应用
JP2024535009A (ja) ニルセビマブによる呼吸器合胞体ウイルス下気道感染の予防
EP4490180A1 (en) Hmpv antibodies and their use
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies